Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.02.004Source: DataRank Database

Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis is a research paper published in Transplantation and Cellular Therapy (2022). On theSindex it has a DataRank of 0. It has been cited 27 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access27 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 3.55)OA: hybridTopics (27)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (27)

Hua‐Ling Tsai ORCID,Amy E. DeZern ORCID,Lukasz P. Gondek ORCID,Hany Elmariah ORCID,Javier Bolaños‐Meade ORCID

Live enrichment

PubMed:35158092 OpenAlex:https://openalex.org/W4211114063

National Cancer Institute

Grant: P01 CA225618

National Cancer Institute

Grant: P30 CA06973

FWCI

3.55

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.jtct.2022.02.004

publisherhttps://doi.org/10.1016/j.jtct.2022.02.004

publisherhttps://api.elsevier.com/content/article/PII:S2666636722000598?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666636722000598?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35158092

Fields of Study

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia ResearchMultiple Myeloma Research and Treatments

MeSH Terms

Bone MarrowCyclophosphamideGraft vs Host DiseaseHumansMiddle AgedNeoplasm Recurrence, LocalPrimary Myelofibrosis

Keywords

MedicineFludarabineMyelofibrosisCyclophosphamideTotal body irradiationTransplantationHazard ratioInternal medicineSurgeryGastroenterologyAlemtuzumabSplenectomyGraft-versus-host diseaseConfidence intervalBone marrowChemotherapySpleen

Sustainable Development Goals

SDG 0: Good health and well-being